LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Innovative biotech industry can support Europe’s health resilience and autonomy

24/10/2023

NEWS RELEASE

Brussels, 24 October 2023 - EuropaBio, the leading voice for the biotechnology industry in Europe, welcomes the adoption of a Commission Communication on shortages of medicines. The ever-evolving global landscape and experience from the COVID-19 pandemic show the need for a comprehensive strategy for Europe to become more resilient and autonomous for its healthcare needs.

The actions outlined in the Communication are welcomed but it is critical that EU actions in this regard are not limited to essential medicines but aim to address Europe’s growing dependency on third countries for innovation medicines. Beyond immediate actions for the upcoming months, mid- to long-term EU actions on shortages must be part of a true European industrial strategy and understood as a strategic investment in our future.

Dr. Claire Skentelbery, Director-General of EuropaBio said: “Securing the supply of essential medicines is important but Europe's strategic autonomy and resilience hinge on its ability to reposition itself as a global leader in healthcare innovation. The biotech and biomanufacturing ecosystems are key partners for resilience and autonomy but they need enabling policies and decisions from European policymakers .”

The entire biotech industry is an essential partner to enhance the EU’s strategic autonomy, including in healthcare. The intricate processes involved in the manufacturing biological medicines, APIs, and intermediate ingredients require cutting-edge technologies that Europe can lead on. As biologics continue to represent a growing share of the global pipeline, Europe should harness the potential of biotech to deliver a resilient, competitive, and sustainable EU by supporting healthcare biotech and biomanufacturing in Europe and collaborating with global partners to strengthen supply chains.

Innovative biotech industry can support Europe’s health resilience and autonomy


Download
Share
Adrian Lincoln
Adrian Lincoln

Related posts

07/07/2025

EuropaBio Position on the Critical Medicines Act


Read more
03/07/2025

Life Sciences Strategy Embraces Biotech for Global Impact


Read more
26/06/2025

EuropaBio AGM 2025: Association Chair, Executive Committee and Board announced


Read more

Important links

  • EuropaBio Position on the Critical Medicines Act
  • Life Sciences Strategy Embraces Biotech for Global Impact

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.